Metabolic and vascular outcomes after transition to the MiniMed 780G system in adults ≥65 years with type 1 diabetes: a randomised, single-centre study
Primary result · TIRResult — go to the resultAdjusted between-group difference 15.7 % 95% CI 8.6–22.6Authors' conclusion
The MiniMed 780G system appears effective for glycaemic management and safe for use in older adults with long-standing type 1 diabetes and a high burden of comorbidities. A non-statistically significant numerical tendency (p>0.05) in the improvement of vascular function that requires further confirmation was also observed.
Study context
- Population
- Adults aged ≥65 years with T1D, HbA1c <86 mmol/mol (10%), naive to hybrid closed-loop technology; single centre29 completed
- Participants
- 34 adults
- Comparison
- Advanced hybrid closed-loop (AHCL) vs control therapy
- Primary endpoint
- Glycaemic management (time in range)
- Follow-up
- 12 months
Methodological detailssingle-centre, open-label (outcome assessors not masked), parallel-group, 1:1 randomisation
- Single-centre
- Open-label (outcome assessors not masked)
- Parallel-group
- 1:1 randomisation
Primary result
TIR
Adjusted between-group difference
15.7 %
95% CI 8.6–22.6
As reported in the abstract
- AHCL: TIR increased from 57.4% at baseline to 79.7% at 12 months
- P < 0.001
Secondary outcomes
| Outcome | Adjusted between-group difference (mmol/mol) (95% CI) | |
|---|---|---|
| HbA1c−0.46%; −0.89%, −0.04% | −5 (−9.7 to −0.4) | |
| −10−505Difference, mmol/mol (linear scale) |
Hyperglycaemia (TAR and TAR 2) in AHCL group
- Reductions in TAR and TAR 2 in AHCL group
- nominal p<0.001; p<0.001
Microvascular function (post-occlusive reactive hyperaemia) in AHCL group
- Shortening of time to maximal flow; favourable numerical trend
- nominal p>0.05
Retinal vascular status (AI-assessed) · throughout follow-up
- Remained stable in both eyes
- nominal p=0.710 and p=0.563
Safety
Hypoglycaemia (TBR and TBR 2) in AHCL group
- No increase in TBR and TBR 2
- nominal p=0.463; p=1
Serious adverse events, DKA, severe hypoglycaemia
- No serious adverse events, DKA or severe hypoglycaemia
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →